Back

Tafamidis versus liver transplantation as first-line therapy for hereditary transthyretin amyloidosis

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Hot topics in myocardial and pericardial diseases Infiltrative Myocardial Disease ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Vincent Algalarrondo

Hospital Bichat-Claude Bernard, Paris (France)

8 More presentations in this session

Presentation thumbnail
Role of 18FDG(fluorodeoxyglucose)-PET (positron emission tomography) for differential diagnosis of pericardial disease
Doctor C. Hyeon (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Interim analysis of data from a long-term, extension trial of tafamidis meglumine in patients with transthyretin amyloid cardiomyopathy
Doctor S. Gottlieb (Baltimore, US)
Abstract Slides Video
Presentation thumbnail
Myocardial perfusion mapping in cardiac amyloidosis- exploring the spectrum from infiltration to ischaemia
Doctor T. Kotecha (London, GB)
Abstract Slides Video
Presentation thumbnail
The increased serum level of troponin T after immunosuppression therapy reflects sustained myocardial FDG accumulation in cardiac sarcoidosis
Doctor R. Morimoto (Nagoya, JP)
Abstract Slides Video
Presentation thumbnail
Anti-heart and anti-intercalated disk autoantibodies: possible novel biomarkers of cardiac sarcoidosis
Professor A. Caforio (Padova, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Hot topics in myocardial and pericardial diseases

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources